BICO Group AB Class B BICO
OMXSTO · Sweden · Health Technology
SEK 21.55-0.30 (-1.37%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Gross margin surged to 59% and adjusted EBITDA turned positive, driven by strong consumables sales and a major EUR50 million licensing deal.
BICO Group AB (CLLKF) reports 11% organic growth amidst currency headwinds and restructuring costs, while focusing on AI-driven lab automation and financial strengthening.
BICO Group (OM:BICO) remains in the red, with net losses increasing at an annual rate of 43% over the past five years and a persistently negative profit margin. While the company is projected to stay unprofitable for at least the next three years, analysts expect revenue to grow at 4.38% per year, slightly outpacing the Swedish market average of 3.7%. Amid weak share price stability and no track record of profitability, BICO’s 1x Price-To-Sales Ratio stands out as considerably lower than both...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.